Oncology and Haematology

Our ultimate vision is to prevent and provide cures for cancer in all its forms. Recognizing that no single intervention can achieve this comprehensive goal, we strive to deeply understand the disease, its complexities, and its impact on patients.

We are proud to have the broadest and most diverse pipeline in oncology, with more than 20 immunotherapy molecules currently in development. Since 2011, we have introduced 18 oncology medicines. Our efforts are united by a commitment to exploring therapeutic combinations and pursuing personalized medicines.

Reflecting our pharma strategy, we aim to bolster end-to-end investment in key disease areas (lung cancer, breast cancer, and malignant hematological conditions), while continually seeking transformative medicines in other areas. This integrated approach ensures that we address the full spectrum of patient needs, from prevention and diagnosis to treatment and beyond.

• Breast

• Lung

• Malignant haematology (including multiple myeloma (MM), lymphoma, acute myeloid leukemia (AML))

• Transformative therapies in other indications - notably including colorectal cancer (CRC), prostate, bladder

• Oncogenic drivers

• Cancer cell dependencies

• Antibody Drug Conjugates (ADCs)

• Cancer immunotherapy - including TCEs, bispecifics, innate and stromal cell

• Allogeneic cell therapies

If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you.